WELBLU, designed to combat Dengue virus infections, is a pioneering technology product. This cutting-edge technology combines the administration of a repurposed sublingual drug formulation in combination with a low-wavelength emitting visible light from a wristband device, representing a revolutionary approach to treating dengue infections.

“A recent in-vitro study has shown that Welblu is effective against all four serotypes of the Dengue virus (DENV1, DENV2, DENV3, and DENV4), with positive assay results confirming it efficacy for invivo use” This finding marks an significant milestone in the development of a comprehensive treatment for the globally affected

At the heart of WELBLU’s treatment is the disintegration of double-enveloped lipid viruses. We utilize advanced drug- device integration technology that enhances the drug’s activity using visible light to effectively neutralize the virus by breaking down its lipid envelope and modulating the host immune response.
Dengue infection presents two interrelated pathological phases:

1. Virus-Triggered Phase: In this initial phase, our therapy directly targets and neutralizes the Dengue virus.
2. Immune Hyper-Response Phase: This subsequent phase can occur even after the virus is cleared, driven by the host’s immune response.

Our approach goes beyond simply targeting the virus. WELBLU’s treatment also addresses common complications associated with Dengue, such as oxidative stress and inflammation. By tackling both viral and host factors, we offer a holistic solution for managing Dengue infection, enhancing patient outcomes and overall health.